Stock Research: Nektar

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Nektar

NasdaqGS:NKTR US6402681083
6
  • Value
    6
  • Growth
    20
  • Safety
    Safety
    21
  • Combined
    1
  • Sentiment
    37
  • 360° View
    360° View
    6
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Nektar Therapeutics is a clinical-stage biotechnology company developing treatments for immunological dysfunction in autoimmune and chronic inflammatory diseases and oncology. The company focuses on medicines targeting biological pathways to stimulate the immune response to fight cancer. Nektar Therapeutics operates in the biotechnology industry. In the last fiscal year, the company had $400 million in market cap, profits of $68 million, revenue of $98 million, and 61 employees.

more
Index
NASDAQ
D.J. US Pharmaceutical
S&P MIDCAP
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
20 73 39 75
Safety
Safety
21 93 94 77
Sentiment
37 16 4 20
360° View
360° View
6 49 60 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
97 17 1 29
Opinions Change
68 50 50 50
Pro Holdings
n/a 70 19 78
Market Pulse
11 15 13 14
Sentiment
37 16 4 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
20 73 39 75
Safety Safety
21 93 94 77
Combined
1 81 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
81 81 81 8
Price vs. Earnings (P/E)
5 49 74 14
Price vs. Book (P/B)
9 28 81 42
Dividend Yield
1 1 1 1
Value
6 22 77 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
8 4 6 97
Profit Growth
17 71 66 25
Capital Growth
4 85 100 85
Stock Returns
100 87 5 43
Growth
20 73 39 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
22 100 100 100
Refinancing
58 92 100 71
Liquidity
26 25 22 11
Safety Safety
21 93 94 77

Similar Stocks

Discover high‑ranked alternatives to Nektar and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: